Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia
NCT ID: NCT06348095
Last Updated: 2024-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
72 participants
INTERVENTIONAL
2024-05-27
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy Children
NCT02640352
Probiotic in Infant Growth, Allergy and Immunity Study
NCT06412042
Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses
NCT00318695
Role of Probiotics as Adjunct Therapy Along With Standard Care in Decreasing Hospital Stay and Improving Symptoms in Pediatric Patients Admitted With Severe Pneumonia
NCT06323642
The Safety and Efficacy of Probiotic for Improving Intestinal and Immune Function
NCT06779994
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotics group
2B CFU/ strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure.
Probiotic
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
Placebo group
Maltodextrin, one strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure.
Placebo
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
Placebo
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Infants and young children aged 6 months to 3 years;
3. The course of the disease is \<48 h;
4. The family members of the children are informed about the study and sign the informed consent form.
Exclusion Criteria
2. Cardiovascular disease and congenital tracheal dysplasia;
3. pneumonia induced by other causes;
4. Dysplasia of bronchial and pulmonary tracts;
5. premature infants;
6. Combined with immunosuppressive diseases;
7. Presence of mental illness.
6 Months
3 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wecare Probiotics Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WK2024004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.